{
    "info": {
        "nct_id": "NCT04566978",
        "official_title": "A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients With Relapsed/Refractory DLBCL",
        "inclusion_criteria": "A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, meet the following criteria to be eligible for inclusion in the study:\n\n* Measurable disease by Lugano criteria, with at least one lesion outside of the liver\n* Patients must have eGFR >50 mL/min/1.73m2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, a patient who meets any of the following criteria will be excluded from the study:\n\n* Patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity.\n* Has not yet recovered (i.e. ≤ Grade 1 or baseline) from any acute toxicities from prior anticancer therapy except for laboratory changes as described in inclusion criteria in study 17-421, except as noted. NOTE: Patients with chronic or stable toxicity following approved therapy, such as mild persistent neuropathy, are allowed.\n* Has received radiation therapy within 14 days of first administration of study drug or has not recovered (i.e. ≤ Grade 1 or baseline) from adverse events, except for laboratory changes as described in inclusion criteria, except as noted. NOTE: Patients with chronic or stable toxicity, such as mild persistent neuropathy, are allowed.\n* Women who are pregnant, breastfeeding *Postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation. Pregnancy testing and screening will be performed per MSK and Department of Radiology standard pregnancy screening guidelines.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Measurable disease by Lugano criteria, with at least one lesion outside of the liver",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by Lugano criteria",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "by Lugano criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one lesion outside of the liver",
                    "criterion": "lesion location",
                    "requirements": [
                        {
                            "requirement_type": "number of lesions outside liver",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, meet the following criteria to be eligible for inclusion in the study:",
            "criterions": [
                {
                    "exact_snippets": "eligible for DLBCL expansion cohort 9 in study 17-421",
                    "criterion": "eligibility for DLBCL expansion cohort 9 in study 17-421",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have eGFR >50 mL/min/1.73m2.",
            "criterions": [
                {
                    "exact_snippets": "eGFR >50 mL/min/1.73m2",
                    "criterion": "eGFR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "mL/min/1.73m2"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, a patient who meets any of the following criteria will be excluded from the study:",
            "criterions": [
                {
                    "exact_snippets": "A patient must be eligible for DLBCL expansion cohort 9 in study 17-421",
                    "criterion": "eligibility for DLBCL expansion cohort 9 in study 17-421",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity.",
            "criterions": [
                {
                    "exact_snippets": "permanently discontinued anti-cancer immune modulating therapies",
                    "criterion": "anti-cancer immune modulating therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_status",
                            "expected_value": "permanently discontinued"
                        }
                    ]
                },
                {
                    "exact_snippets": "due to drug-related toxicity",
                    "criterion": "drug-related toxicity",
                    "requirements": [
                        {
                            "requirement_type": "cause_of_discontinuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received radiation therapy within 14 days of first administration of study drug or has not recovered (i.e. ≤ Grade 1 or baseline) from adverse events, except for laboratory changes as described in inclusion criteria, except as noted. NOTE: Patients with chronic or stable toxicity, such as mild persistent neuropathy, are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Has received radiation therapy within 14 days of first administration of study drug",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiation therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered (i.e. ≤ Grade 1 or baseline) from adverse events, except for laboratory changes as described in inclusion criteria, except as noted. NOTE: Patients with chronic or stable toxicity, such as mild persistent neuropathy, are allowed.",
                    "criterion": "recovery from adverse events",
                    "requirements": [
                        {
                            "requirement_type": "severity of adverse events",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not yet recovered (i.e. ≤ Grade 1 or baseline) from any acute toxicities from prior anticancer therapy except for laboratory changes as described in inclusion criteria in study 17-421, except as noted. NOTE: Patients with chronic or stable toxicity following approved therapy, such as mild persistent neuropathy, are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Has not yet recovered (i.e. ≤ Grade 1 or baseline) from any acute toxicities from prior anticancer therapy",
                    "criterion": "acute toxicities from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "recovered or at baseline"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for laboratory changes as described in inclusion criteria in study 17-421",
                    "criterion": "laboratory changes from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": "as described in inclusion criteria in study 17-421"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with chronic or stable toxicity following approved therapy, such as mild persistent neuropathy, are allowed.",
                    "criterion": "chronic or stable toxicity following approved therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant, breastfeeding *Postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation. Pregnancy testing and screening will be performed per MSK and Department of Radiology standard pregnancy screening guidelines.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhoeic duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "women with documented hysterectomy or tubal ligation",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "hysterectomy or tubal ligation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnancy testing and screening will be performed per MSK and Department of Radiology standard pregnancy screening guidelines",
                    "criterion": "pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "testing per guidelines",
                            "expected_value": "MSK and Department of Radiology standard pregnancy screening guidelines"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}